Connor, Clark & Lunn Investment Management (CC&L)
NGM

Connor, Clark & Lunn Investment Management (CC&L)’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-98,037
Closed -$156K – 1768
2024
Q1 		$156K Buy
+98,037
New +$145K ﹤0.01% 1428
2023
Q3 		– Sell
-121,685
Closed -$315K – 1595
2023
Q2 		$315K Sell
121,685
-72,466
-37% -$259K ﹤0.01% 1096
2023
Q1 		$792K Buy
194,151
+39,741
+26% +$184K ﹤0.01% 776
2022
Q4 		$775K Buy
154,410
+43,711
+39% +$274K ﹤0.01% 771
2022
Q3 		$1.45M Buy
110,699
+74,646
+207% +$1.13M 0.01% 569
2022
Q2 		$462K Buy
+36,053
New +$499K ﹤0.01% 800

Connor, Clark & Lunn Investment Management (CC&L)'s NGM Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 98,037 shares — an estimated $156K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NGM in Q2 2022 and held it in 6 quarters. The position peaked at $1.45M in Q3 2022. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 98,037 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $156K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 6 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.45M in Q3 2022.
  • 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.